GlassScriptPhysician profile
Brian R Shunk
NPI 1548326374
$1,517.35
in general payments reported to CMS, 2019-2025
18 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.91 · 2021: $122 · 2022: $99.16 · 2023: $246 · 2024: $445 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.29 | 2023-2025 | Dalvance, Ubrelvy |
| Novo Nordisk INC | $262.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $160.21 | 2021-2025 | |
| Lilly USA, LLC | $159.88 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $127.95 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $62.46 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $47.50 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $39.76 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $26.76 | 2019-2024 | Airsupra |
| Viatris Specialty LLC | $22.03 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.40 | 2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $17.53 | 2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Eisai INC. | $15.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.55 | 2024 | Camzyos |
| Phathom Pharmaceuticals, INC. | $14.99 | 2024 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $14.62 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $13.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Shunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.